STOCK MARKET BSE NSE

Samples of all Covid patients being sent for genome sequencing: BBMP chief

A team of experts is conducting a study on it and more information on the severity and difference between Delta and Delta-plus variants will be known only after the study is completed.

Published: 23rd June 2021 05:37 AM  |   Last Updated: 23rd June 2021 02:38 PM   |  A+A-

A medic at the Spicehealth Genome Sequencing Laboratory | Shekhar yadav

By Express News Service

BENGALURU: Samples of all those who have tested Covid-positive are being sent for genome sequencing to study the spread, if any, of Covid Delta variant in the city, said Bruhat Bengaluru Mahanagara Palike (BBMP) Chief Commissioner Gaurav Gupta on Tuesday.

A team of experts is conducting a study on it and more information on the severity and difference between Delta and Delta-plus variants will be known only after the study is completed. The Delta variant has been found in Maharashtra, Madhya Pradesh and some other states, he added.

“Chief Minister BS Yediyurappa’s decision to conduct RT-PCR tests and monitor those travelling from Maharashtra is final. Earlier too, people coming from neighbouring states were subjected to RT-PCR tests. BBMP is ready to make the RT-PCR test mandatory if it is considered essential to detect the Delta variant. A death audit is being conducted to determine the variants,” he said.

On the vaccination drive, he said that so far, 63 per cent of people above 40 years of age in the city have taken the first dose and of them, 81 per cent have completed their second shot too. Also, 42 per cent of people aged above 18 have taken the first dose.

Vaccine, sample collection vans flagged off
Chief Minister B S Yediyurappa on Tuesday flagged off vaccine vehicles and a sample collection van. The vehicles were donated to BBMP by Parexel, Flowserve, Keysight, United Way Bengaluru, Tata Motors and Collins Aerospace. They have been designed by ShanMukha Innovations in collaboration with IISc.

ALSO WATCH | Bharat Biotech's Covaxin shows 77.8% efficacy in Phase 3 trials



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp